Skip to content

Search

The ETO2 transcriptional cofactor maintains acute leukemia by driving a MYB/EP300-dependent stemness program

Transcriptional cofactors of the ETO family are recurrent fusion partners in acute leukemia. We characterized the ETO2 regulome by integrating transcriptomic and chromatin binding analyses in human erythroleukemia xenografts and controlled ETO2 depletion models. We demonstrate that beyond its well-established repressive activity, ETO2 directly activates transcription of MYB, among other genes.

Childhood Cancer Incidence and Survival in South Australia and the Northern Territory, 1990–2017, with Emphasis on Indigenous Peoples

Reports of a rise in childhood cancer incidence in Australia and globally prompted the investigation of cancer incidence and survival in South Australia and the Northern Territory over a 28-year period, with emphasis on Indigenous peoples.

The critical role of the bone marrow stromal microenvironment for the development of drug screening platforms in leukemia

Extensive research over the past 50 years has resulted in significant improvements in survival for patients diagnosed with leukemia. Despite this, a subgroup of patients harboring high-risk genetic alterations still suffer from poor outcomes. There is a desperate need for new treatments to improve survival, yet consistent failure exists in the translation of in vitro drug development to clinical application.

Histological predictors of outcome for cutaneous squamous cell carcinoma in renal transplant patients: A case-control study

Cutaneous squamous cell carcinoma is a significant cause of morbidity for immunosuppressed patients such as organ transplant recipients; however, histological parameters which predict the likelihood of tumor progression are typically based on general population studies in which immunosuppressed patients represent only a small fraction of cases. 

Insights into the Clinical, Biological and Therapeutic Impact of Copy Number Alteration in Cancer

Copy number alterations (CNAs), resulting from the gain or loss of genetic material from as little as 50 base pairs or as big as entire chromosome(s), have been associated with many congenital diseases, de novo syndromes and cancer. It is established that CNAs disturb the dosage of genomic regions including enhancers/promoters, long non-coding RNA and gene(s) among others, ultimately leading to an altered balance of key cellular functions.

An Anti-VEGF-B Antibody Reduces Abnormal Tumor Vasculature and Enhances the Effects of Chemotherapy

The vascular endothelial growth factors and their receptors are key regulators of blood vessel formation, including in tumors, where their deregulated function can promote the production of aberrant, leaky blood vessels, supporting tumor development. 

Beyond the horizon: improving cancer outcomes for Indigenous children

Dr Jessica Buck, a researcher at The Kids Research Institute Australia Cancer Centre and a Kamilaroi woman, is on a mission to address the unique challenges faced by Aboriginal and Torres Strait Islander children with cancer.

Childhood cancers not on the rise in SA and NT, but disparity remains for Indigenous children in the NT

Despite national and global reports of rising incidences of cancer affecting children and young people, a new analysis has found rates of childhood cancer have remained unchanged over the last 30 years in South Australia and the Northern Territory.

Precision medicine offering new hope for kids with aggressive cancers

A world-first study involving more than 100 cancer researchers and clinicians across Australia – including from The Kids Research Institute Australia and Perth Children’s Hospital – has shown that precision medicine can significantly improve outcomes for children with high-risk cancer.

Raine Foundation grants support exciting projects in childhood cancer and newborn infections

Two The Kids Research Institute Australia researchers have been awarded prestigious grants from the Raine Medical Research Foundation for projects in childhood cancer and newborn infection control.